API | fontolizumab

fontolizumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank

Active Ingredient History

NOW

Fontolizumab is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease. A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
fontolizumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Interferon gamma (Homo sapiens) ^UniProt
- Interferon gamma (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

asn100 | fontolizumab | huzaf

Organizations (9)

Research & Development (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Arthritis, Rheumatoid (Phase 2)

Pneumonia, Staphylococcal (Phase 2)

Pneumonia, Ventilator-Associated (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial Organizations: 9

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue